What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Alberto Bardelli spends much of his time researching Cancer research, Cancer, Colorectal cancer, KRAS and Cetuximab.
The Cancer research study combines topics in areas such as Epidermal growth factor receptor, Immunology, Signal transduction, Growth factor receptor and Drug resistance.
The concepts of his Cancer study are interwoven with issues in Mutation, Gene, Biopsy and Personalized medicine.
His Colorectal cancer research includes elements of Metastasis and Bioinformatics.
As part of the same scientific family, Alberto Bardelli usually focuses on KRAS, concentrating on Targeted therapy and intersecting with Predictive marker and Progressive disease.
His study of Panitumumab is a part of Cetuximab.
His most cited work include:
- High frequency of mutations of the PIK3CA gene in human cancers (2829 citations)
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies (2454 citations)
- International network of cancer genome projects (1611 citations)
What are the main themes of his work throughout his whole career to date?
Cancer research, Colorectal cancer, Internal medicine, Oncology and Cancer are his primary areas of study.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Mutation, Immunology, Kinase and Drug resistance.
His Colorectal cancer study incorporates themes from Blockade, Targeted therapy and Epidermal growth factor receptor.
His Oncology study combines topics from a wide range of disciplines, such as Clinical trial, Irinotecan, Lapatinib, Biomarker and Breast cancer.
His Cancer research incorporates elements of Gene, Disease, Pathology and Bioinformatics.
His KRAS research includes themes of Mutant and PTEN.
He most often published in these fields:
- Cancer research (48.66%)
- Colorectal cancer (45.97%)
- Internal medicine (33.25%)
What were the highlights of his more recent work (between 2018-2021)?
- Colorectal cancer (45.97%)
- Cancer research (48.66%)
- Internal medicine (33.25%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Colorectal cancer, Cancer research, Internal medicine, Oncology and Cancer.
Alberto Bardelli is involved in the study of Colorectal cancer that focuses on KRAS in particular.
His Cancer research study integrates concerns from other disciplines, such as Exome sequencing, Cancer cell, DNA repair, DNA mismatch repair and Drug resistance.
His work on Liquid biopsy, Targeted therapy, Circulating tumor DNA and Cohort study is typically connected to Clinical Practice as part of general Internal medicine study, connecting several disciplines of science.
His research in Oncology intersects with topics in Clinical trial, Pertuzumab, Lapatinib, Trastuzumab and Confidence interval.
His studies deal with areas such as Reprogramming, Beta, Lung and CD8 as well as Cancer.
Between 2018 and 2021, his most popular works were:
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (157 citations)
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. (102 citations)
- Adaptive mutability of colorectal cancers in response to targeted therapies. (88 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Alberto Bardelli mostly deals with Colorectal cancer, Cancer research, Internal medicine, Oncology and Liquid biopsy.
His work in the fields of Colorectal cancer, such as KRAS, intersects with other areas such as Workflow.
As a member of one scientific family, he mostly works in the field of KRAS, focusing on Blockade and, on occasion, Receptor tyrosine kinase, Basal, Cell culture, Growth factor and Growth factor receptor.
His Cancer research research is multidisciplinary, incorporating perspectives in Mutation, Cancer cell, Immune checkpoint and DNA repair.
Alberto Bardelli combines subjects such as Clinical trial, Young adult, Targeted therapy, Age of onset and Primary tumor with his study of Oncology.
His Liquid biopsy study combines topics in areas such as Brain cancer, Cell free, DNA and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
